JANX
Janux Therapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeJanux reported Q2 2026 results with a strong $970.9M cash position and raised revenue guidance (151% improvement to $34.5M consensus for 2026), but faced significant analyst downgrades following mixed Phase 1 data for lead candidate JANX007, with Barclays and UBS citing concerns about efficacy, safety profile optimization challenges, and lack of near-term catalysts. The stock has declined 47% year-over-year despite board strengthening and pipeline expansion, reflecting investor skepticism about JANX007's path to commercialization.
Red flags
- •Lead candidate JANX007 Phase 1 data characterized as 'mixed' by multiple analysts, triggering two major downgrades (Barclays to Underweight, UBS to Neutral)
- •Stock down 47% YoY and 41% in past 6 months despite improved cash position and revenue guidance
- •Two major analyst price target cuts (Barclays $29→$14, UBS $57→$15) citing probability-of-success concerns for lead program
- •Ongoing net losses ($21.97M in Q2 2026) with no clear path to profitability; 12-month cash runway guidance suggests significant dilution risk
- •Lack of near-term catalysts identified by UBS despite pipeline expansion (JANX011, JANX013)
Fund 13D/13G Filings (3)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).